|
27 Sep 2025 |
Sun Pharmaceutical
|
Consensus Share Price Target
|
1586.70 |
1928.05 |
- |
21.51 |
buy
|
|
|
|
|
30 Jul 2022
|
Sun Pharmaceutical
|
ICICI Direct
|
1586.70
|
1125.00
|
943.20
(68.23%)
|
Target met |
Buy
|
|
|
|
|
13 Jun 2022
|
Sun Pharmaceutical
|
Geojit BNP Paribas
|
1586.70
|
970.00
|
793.40
(99.99%)
|
Target met |
Buy
|
|
|
|
|
31 May 2022
|
Sun Pharmaceutical
|
SMC online
|
1586.70
|
|
865.10
(83.41%)
|
|
Results Update
|
|
|
|
|
31 May 2022
|
Sun Pharmaceutical
|
ICICI Securities Limited
|
1586.70
|
961.00
|
888.30
(78.62%)
|
Target met |
Accumulate
|
|
|
Sun Pharmaceutical’s (Sun) reported Q4FY22 performance was marginally lower than our estimates. Consolidated revenue grew 10.8% YoY to Rs94.5bn (and adj. PAT was up 17.8% to Rs15.8bn. EBITDA margin was 24.8% against our estimate of 25.6%. Specialty portfolio grew 1.6% QoQ to US$186mn versus our estimate of US$185mn led by growth in Ilumya, Cequa and
Odomzo, largely offset by increased generic completion in Absorica.
|
|
31 May 2022
|
Sun Pharmaceutical
|
ICICI Direct
|
1586.70
|
1070.00
|
839.25
(89.06%)
|
Target met |
Buy
|
|
|
|
|
31 May 2022
|
Sun Pharmaceutical
|
BOB Capital Markets Ltd.
|
1586.70
|
1100.00
|
839.25
(89.06%)
|
|
Buy
|
|
|
Q4 EBITDA/adj. PAT declined 17%/28% QoQ (+6%/-5% YoY) due to 350bps QoQ contraction in operating margin
|
|
31 May 2022
|
Sun Pharmaceutical
|
Motilal Oswal
|
1586.70
|
1040.00
|
860.60
(84.37%)
|
Target met |
Buy
|
|
|
|
|
31 May 2022
|
Sun Pharmaceutical
|
Prabhudas Lilladhar
|
1586.70
|
1020.00
|
859.55
(84.60%)
|
Target met |
Buy
|
|
|
|
|
24 Feb 2022
|
Sun Pharmaceutical
|
BOB Capital Markets Ltd.
|
1586.70
|
1045.00
|
831.55
(90.81%)
|
Target met |
Buy
|
|
|
SUNP, through subsidiary Taro Pharma, to acquire Galderma's skincare arm Alchemee in US$ 90mn all-cash deal
|
|
02 Feb 2022
|
Sun Pharmaceutical
|
ICICI Securities Limited
|
1586.70
|
1075.00
|
890.65
(78.15%)
|
|
Buy
|
|
|
|